Literature DB >> 11103811

Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.

M Shaif-Muthana1, C McIntyre, K Sisley, I Rennie, A Murray.   

Abstract

Uveal melanoma is an aggressive malignancy with a poor prognosis despite current therapeutic intervention. These tumors have been shown to be antigenic because they express a number of melanoma-associated antigens and are therefore attractive targets for immunotherapy. Here, we investigated the immunogenicity of uveal melanoma cells that have undergone apoptosis and compared this with their necrotic or live counter-parts. The fate of the tumor antigens in these cells largely depends on their ability to be processed and phagocytosed by dendritic cells (DCs). Flow cytometric analysis shows that human DCs form conjugates more efficiently with dead uveal melanoma cells, and consequently these are effective stimuli of lymphocyte proliferation. However, only DCs pulsed with apoptotic cells were able to induce proliferation of CD8+ cytotoxic T cells and stimulate antigen-specific T cells. This study demonstrates for the first time that DCs derived from melanoma patients process and present antigens derived from both HLA-matched or HLA-mismatched human apoptotic tumor cells stimulating both CD4+ and CD8+ T cells. This approach may be important to the development of DC-based immunotherapies for melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103811

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Elke S Bergmann-Leitner; Steven E Finkelstein; Stephan Frank; Nicholas P Restifo
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

Review 2.  Natural endogenous adjuvants.

Authors:  Kenneth L Rock; Arron Hearn; Chun-Jen Chen; Yan Shi
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

Review 3.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

4.  Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.

Authors:  Jianping Pan; Minghui Zhang; Jianli Wang; Qingqing Wang; Dajing Xia; Wenji Sun; Lihuang Zhang; Hai Yu; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2005-02-12       Impact factor: 4.553

Review 5.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

6.  Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.

Authors:  Jennifer Carlring; Munitta Shaif-Muthana; Karen Sisley; Ian G Rennie; Anna K Murray
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 7.  DNA vaccines for HIV: challenges and opportunities.

Authors:  David A Hokey; David B Weiner
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

8.  Differential responses of cord and adult blood-derived dendritic cells to dying cells.

Authors:  On Hang Wong; Fang-Ping Huang; Alan K S Chiang
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

9.  Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer.

Authors:  Michael R Shurin; Alla I Potapovich; Yulia Y Tyurina; Irina L Tourkova; Galina V Shurin; Valerian E Kagan
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Michael J deVeer; Aimin Zhou; Robert H Silverman; Bryan R G Williams; Thomas W Dubensky; Han Ying; Nicholas P Restifo
Journal:  Nat Med       Date:  2002-12-23       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.